Volume 36, Issue 1 (4-2025)
Studies in Medical Sciences 2025, 36(1): 1-12 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sheikhalizadeh Nobar F, Sattari Aqjeh Kohl Y. The frequency of neurological and psychological disorders in patients with bullous pemphigoid. Studies in Medical Sciences 2025; 36 (1) :1-12
URL: http://umj.umsu.ac.ir/article-1-6404-en.html
URL: http://umj.umsu.ac.ir/article-1-6404-en.html
Assistant Professor, Department of Dermatology, Tabriz University of Medical Sciences (Corresponding Author) , Sheikhalizadehf@tbzmed.ac.ir
Abstract: (649 Views)
Background & Aims: Bullous pemphigoid is the most common autoimmune blistering skin disease, primarily affecting the elderly, and has been associated with neurological and psychological comorbidities. This study aimed to investigate the prevalence of these disorders in patients with bullous pemphigoid and explore the potential relationship between bullous pemphigoid and neurological/psychological diseases.
Materials & Methods: This was a retrospective cross-sectional analytical study involving 100 patients with bullous pemphigoid admitted to Sinai Hospital in Tabriz over a ten-year period (2012–2022). Data were extracted from patient records and analyzed using SPSS software.
Results: The mean age of the patients was 73.12 years. Forty-two percent (42%) were male, and 58% were female. Sixty-seven percent (67%) had at least one neurological or psychological disorder. The most common neurological disease was stroke (26%), while the least common was Parkinson’s disease (1%). Depression was observed in 15% of patients.
Conclusion: The findings indicate a high prevalence of neurological and psychological disorders in patients with bullous pemphigoid. Early diagnosis and management of these comorbidities may improve patients’ quality of life
Materials & Methods: This was a retrospective cross-sectional analytical study involving 100 patients with bullous pemphigoid admitted to Sinai Hospital in Tabriz over a ten-year period (2012–2022). Data were extracted from patient records and analyzed using SPSS software.
Results: The mean age of the patients was 73.12 years. Forty-two percent (42%) were male, and 58% were female. Sixty-seven percent (67%) had at least one neurological or psychological disorder. The most common neurological disease was stroke (26%), while the least common was Parkinson’s disease (1%). Depression was observed in 15% of patients.
Conclusion: The findings indicate a high prevalence of neurological and psychological disorders in patients with bullous pemphigoid. Early diagnosis and management of these comorbidities may improve patients’ quality of life
References
1. Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers 2025;11(1):12. [DOI:10.1038/s41572-025-00605-6] [PMID]
2. Chou PY, Yu CL, Wen CN, Tu YK, Chi CC. Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis. JAMA Dermatol 2024. [DOI:10.1001/jamadermatol.2024.3425] [PMID]
3. Pratasava V, Sahni VN, Suresh A, Huang S, Are A, Hsu S, et al. Bullous pemphigoid and other pemphigoid dermatoses. Medicina 2021;57(10):1061. [DOI:10.3390/medicina57101061] [PMID] []
4. Persson MS, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol 2022;186(3):414-25. [DOI:10.1111/bjd.20743] [PMID]
5. Chen Q, Wu H, Lyu Y, Xiong J. Associations among bullous pemphigoid and various neurological diseases: A systematic review and meta-analysis. JEADV Clin Pract 2022;1(3):196-206. [DOI:10.1002/jvc2.36]
6. Shen S, Chu M, Miao H, Li L, Fang H, Li X, et al. Assessment of relationships between bullous pemphigoid and neurological diseases: a bidirectional two-sample Mendelian randomization study. Exp Dermatol 2024;33(1):e14869. [DOI:10.1111/exd.14869] [PMID]
7. Smit CP, Gray NA, Visser WI. Bullous pemphigoid and its association with neurological diseases. J Coll Med S Afr 2024;2(1):27. [DOI:10.4102/jcmsa.v2i1.27]
8. Huang IH, Wu PC, Liu CW, Huang YC. Association between bullous pemphigoid and psychiatric disorders: A systematic review and meta-analysis. J Dtsch Dermatol Ges 2022;20(10):1305-12. [DOI:10.1111/ddg.14852]
9. Martin E, Mauer I, Malzahn U, Heuschmann PU, Goebeler M, Benoit S. Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study. J Dtsch Dermatol Ges 2022;20(6):798-805. [DOI:10.1111/ddg.14738]
10. Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol 2023;14:1196999. [DOI:10.3389/fimmu.2023.1196999] [PMID] []
11. Cosimati A, Rossi L, Didona D, Forcella C, Didona B. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: a case report and review of literature. J Oncol Pharm Pract 2021;27(3):727-33. [DOI:10.1177/1078155220946370] [PMID]
12. Deotto ML, Spiller A, Sernicola A, Alaibac M. Bullous pemphigoid: An immune disorder related to aging. Exp Ther Med 2022;23(1):50. [DOI:10.3892/etm.2021.10972] [PMID] []
13. Cole C, Borradori L, Amber KT. Deciphering the contribution of BP230 autoantibodies in bullous pemphigoid. Antibodies 2022;11(3):44. [DOI:10.3390/antib11030044] [PMID] []
14. Salemme A, Fania L, Scarabello A, Caproni M, Marzano AV, Cozzani E, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol 2022;87(1):56-63. [DOI:10.1016/j.jaad.2022.02.036] [PMID]
15. Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha AA. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol 2023;14:1159351. [DOI:10.3389/fimmu.2023.1159351] [PMID] []
16. Lu L, Chen L, Xu Y, Liu A. Global incidence and prevalence of bullous pemphigoid: a systematic review and meta-analysis. J Cosmet Dermatol 2022;21(10):4818-35. [DOI:10.1111/jocd.14797] [PMID]
17. Shalata W, Weissmann S, Itzhaki Gabay S, Sheva K, Abu Saleh O, Jama AA, et al. A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors. Cancers 2022;14(21):5451. [DOI:10.3390/cancers14215451] [PMID] []
18. Sánchez-García V, Pérez-Alcaraz L, Belinchón-Romero I, Ramos-Rincón JM. Comorbidities in patients with autoimmune bullous disorders: hospital-based registry study. Life 2022;12(4):595. [DOI:10.3390/life12040595] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
